Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.
Olgun N, Cecen E, Ince D, Kizmazoglu D, Baysal B, Onal A, Ozdogan O, Guleryuz H, Cetingoz R, Demiral A, Olguner M, Celik A, Kamer S, Ozer E, Altun Z, Aktas S.
Olgun N, et al. Among authors: cetingoz r.
Front Oncol. 2022 Dec 23;12:1041443. doi: 10.3389/fonc.2022.1041443. eCollection 2022.
Front Oncol. 2022.
PMID: 36620564
Free PMC article.